Clinical Trials Logo

Adenocarcinoma in Situ clinical trials

View clinical trials related to Adenocarcinoma in Situ.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06031181 Recruiting - Lung Adenocarcinoma Clinical Trials

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Start date: March 31, 2023
Phase: Phase 3
Study type: Interventional

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1019. The goal of this clinical trial is to confirm the therapeutic effect of sublobar resection for AIS/MIA diagnosed by intraoperative frozen section.

NCT ID: NCT05210348 Recruiting - Cervical Cancer Clinical Trials

Clinical Evaluation of Detection of High Risk HPV in Urine

Urine-hrHPV
Start date: September 15, 2021
Phase:
Study type: Observational

Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer. Traditional HPV testing is based on the cells sample shed from the cervix. Recent studies have shown that urine HPV detection can be used as a new HPV detection method. This study intends to include patients undergoing TCT /HPV test/colposcopy in the department of gynecological diseases of the hospital, and collect urine samples and cervical swab samples. Sanger sequencing and cervical swab HPV test results were compared to evaluate the accuracy and clinical validity of urine HPV test combined with clinical diagnosis results of cases.

NCT ID: NCT04452058 Recruiting - Lung Cancer Clinical Trials

CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC

TOP-RLC
Start date: August 1, 2019
Phase:
Study type: Observational

The purpose of this study was to investigate whether the combined radiomic model based on radiomic features extracted from focus and perifocal area (5mm) can effectively improve prediction performance of distinguishing precancerous lesions from early-stage lung adenocarcinoma, which could assist clinical decision making for surgery indication. Besides, response and long term clinical benefit of immunotherapy of advanced NSCLC lung cancer patients could also be predicted by this strategy.